Sensus Healthcare, Inc. (SRTS)
| Market Cap | 82.44M |
| Revenue (ttm) | 44.53M |
| Net Income (ttm) | 24.24M |
| Shares Out | 16.39M |
| EPS (ttm) | 1.46 |
| PE Ratio | 3.40 |
| Forward PE | 5.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 142,784 |
| Open | 4.92 |
| Previous Close | 4.96 |
| Day's Range | 4.80 - 5.08 |
| 52-Week Range | 4.80 - 15.25 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | 15.20 (+202.19%) |
| Earnings Date | May 4, 2023 |
About SRTS
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, wh... [Read more]
Financial Performance
In 2022, SRTS's revenue was $44.53 million, an increase of 64.68% compared to the previous year's $27.04 million. Earnings were $24.24 million, an increase of 488.59%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for SRTS stock is "Buy." The 12-month stock price forecast is $15.2, which is an increase of 202.19% from the latest price.
News
7 Stocks to Bet On if You Want to Be Richer Than Elon Musk
If you aspire to one day topple entrepreneurial genius Elon Musk on the net wealth rankings through the equities market exclusively, you're obviously going to need to conduct heavy research on the sto...
Sensus Healthcare announces the Sensus Cloud™; Unveils New Features at American Academy of Dermatology (AAD) Annual Meeting in New Orleans March 17-19
New comprehensive asset and EMR management feature allows users to collect real-time information from the device to manage and maintain multiple machines with Chat GPT New comprehensive asset and EMR ...
7 Overlooked Value Stocks That Could Outperform the Market
With thousands of publicly traded companies to choose from, it's inevitable that a few will make the rounds of overlooked value stocks. These enterprises represent businesses that trade at an attracti...
Sensus Healthcare, Inc. (SRTS) Q4 Earnings and Revenues Lag Estimates
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -34.62% and 1.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st...
Sensus Healthcare Fourth Quarter 2022 Financial Results Include Quarterly Revenues of $13.1 Million
Full-year revenues increased 65% to $44.5 million
Does Sensus Healthcare, Inc. (SRTS) Have the Potential to Rally 81.12% as Wall Street Analysts Expect?
The mean of analysts' price targets for Sensus Healthcare, Inc. (SRTS) points to an 81.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme...
Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q4 Earnings Expected to Decline
Sensus Healthcare, Inc. (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sensus Healthcare to Host Fourth Quarter 2022 Financial Results and Business Update Conference Call on February 9, 2023
BOCA RATON, Fla., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and ...
Wall Street Analysts Predict a 72.6% Upside in Sensus Healthcare, Inc. (SRTS): Here's What You Should Know
The consensus price target hints at a 72.6% upside potential for Sensus Healthcare, Inc. (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...
How 2022's Biggest Healthcare Gainers Could Fare In 2023
Health care stocks were hit hard early in the pandemic but these three have made quite a comeback. This article examines where they could go in 2023
Sensus Healthcare Announces Preliminary Fourth Quarter 2022 Revenues
Fourth quarter revenues to exceed $13 million; full year revenues to exceed $44 million, representing growth of 60%
Down 46.9% in 4 Weeks, Here's Why Sensus Healthcare, Inc. (SRTS) Looks Ripe for a Turnaround
Sensus Healthcare, Inc. (SRTS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analys...
Sensus Healthcare, Inc. (SRTS) Q3 Earnings Lag Estimates
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -8.33% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...
Recent Price Trend in Sensus Healthcare, Inc. (SRTS) is Your Friend, Here's Why
Sensus Healthcare, Inc. (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passe...
Sensus Healthcare to Host Third Quarter 2022 Financial Results and Business Update Conference Call on November 3, 2022
BOCA RATON, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and ...
Sensus Healthcare Introduces Silk™ Laser Hair Removal System
Only portable hair removal laser system with blended wavelengths for all skin phototypes to be launched at the Fall Clinical Dermatology Conference Only portable hair removal laser system with blended...
3 Resilient Medical Stocks to Watch as Rate Hikes Continue
Here we discuss three Medical-Instruments stocks - TMDX, PRCT & SRTS - that continued to grow in the first nine months of 2022 even though three Fed rate hikes dragged broader indices down.
Sensus Healthcare to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BOCA RATON, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effect...
Sensus Healthcare Launches Upgrade to its SRT-100 Vision System with New State-of-the-Art Ultrasound Capabilities
Includes a new ergonomic probe to operate in ideal MHz range to view all layers of skin Includes a new ergonomic probe to operate in ideal MHz range to view all layers of skin
5 Stocks With Recent Price Strength to Enrich Your Portfolio
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are SRTS, SMCI, ULH, ACA and CELH.
Sensus Healthcare, Inc. (SRTS) Q2 Earnings and Revenues Top Estimates
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 16.67% and 17.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
7 Growth Stocks to Buy Now Before They Become Large Caps
Canada's national business paper, The Globe and Mail, recently interviewed a Toronto-based portfolio manager who seeks out smaller growth stocks with the potential to become large caps over the long h...
Sensus Healthcare Takes Order for 10 TransDermal Infusion Systems™ Supporting Hair Enhancement Centers Expansion Along with U.SK Under Skin's Hair-Health Serum
BOCA RATON, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effecti...
Sensus Healthcare to Host Second Quarter 2022 Financial Results and Business Update Conference Call on August 4, 2022
BOCA RATON, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological an...
Sensus Healthcare, Inc. (SRTS) Is a Great Choice for "Trend" Investors, Here's Why
Sensus Healthcare, Inc. (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passe...